SiSaf announces licencing agreement to develop gene therapy for rare bone disease
SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine Research
SiSaf Establishes Strategic Partnership with Avellino Labs
SiSaf Strengthens it’s Leadership Team
« Previous Page
Next Page »
Find out more.
Okay, thank you